Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has issued an update.
QIAGEN N.V. has reported a manager’s transaction involving supervisory board member Toralf Haag, following the implementation of a synthetic share repurchase program. Under the terms of this program, previously approved by shareholders and announced in 2025, every 20 issued QIAGEN shares were consolidated into 19, resulting in Haag’s holdings being reduced by 219 shares to a total of 4,147 common shares, with the transaction executed outside a trading venue and not quantifiable in conventional price and volume terms. The move reflects the technical effects of QIAGEN’s capital measures associated with its synthetic share repurchase, which impact outstanding share counts and individual insider holdings but do not, on their own, indicate a discretionary buy or sell decision by management.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a life sciences and molecular diagnostics company headquartered in Venlo, Netherlands, whose shares are listed on several European exchanges as well as the NYSE and Swiss markets. The company provides sample and assay technologies used in molecular testing across research, applied testing, and clinical diagnostics, serving laboratories, healthcare providers, and biotechnology customers globally.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.